Showing items 1276-1300 of 2549 (102 Page(s) Totally)
<< < 47 48 49 50 51 52 53 54 55 56 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2020-06-01T03:55:42Z |
Accuracy of diabetes diagnosis in health insurance claims data in Taiwan
|
Lin C.-C.;Lai M.-S.;Syu C.Y.;Chang S.C.;Fen-Yu Tseng; Lin C.-C.; Lai M.-S.; Syu C.Y.; Chang S.C.; FEN-YU TSENG |
| 臺大學術典藏 |
2020-06-01T03:55:41Z |
Professional accountability for diabetes care in Taiwan
|
Fen-Yu Tseng;Lai M.-S.;Syu C.-Y.;Lin C.-C.; FEN-YU TSENG; Lai M.-S.; Syu C.-Y.; Lin C.-C. |
| 臺大學術典藏 |
2020-06-01T03:55:36Z |
Subclinical hypothyroidism is associated with increased risk for cancer mortality in adult taiwanese-A 10 years population- Based cohort
|
Huang K.-C.;Lin C.-.C.;Li T.-C.;Li C.-I.;Lin W.-Y.;FEN-YU TSENG; FEN-YU TSENG; Lin W.-Y.; Li C.-I.; Li T.-C.; Lin C.-.C.; Huang K.-C. |
| 臺大學術典藏 |
2020-06-01 |
Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate
|
Wang, T. H.; Chiueh, H. Y.; Chang, Y. L.; Cheng, P. J.; Lee, C. L.; Lin, C. C.; Lin, P. Y.; Yang, W. R.; Hu, J. J.; Yang, C. K.; Chang, Y. K.; Chen, K. H.; Lin, H. H.; Lin, Y. H.; Chen, H. J.; Pan, H. S.; Lau, B. H.; TIFFANY TING-FANG SHIH; JIA-FENG WU; YEN-HSUAN NI; CHIEN-NAN LEE; Zhao, Lu Lu; Lai, Ming Wei; Mu, Shu Chi; YI-CHING TUNG; HONG-YUAN HSU; MEI-HWEI CHANG; Shyu, M. K.; Hwa, H. L.; Su, Y. N.; Shih, J. C.; Chao, K. H.; Chiu, Y. C.; Chang, K. C.; Liu, C. J.; Su, T. H.; Chen, D. S.; Chen, S. M.; Hsu, J. J.; Lo, L. M.; Hsieh, C. L.; Cheng, S. W.; Tsai, M. S.; Lin, L. H.; She, B. Q.; Peng, F. S.; Lin, Y. C.; Chen, C. P.; Huang, J. P.; Yeung, C. Y.; HUEY-LING CHEN; Wen, Wan Hsin |
| 臺大學術典藏 |
2020-05-27T03:38:24Z |
Dynamic functional modules in co-expressed protein interaction networks of dilated cardiomyopathy
|
Lin C.-C.;Hsiang J.-T.;Chia-Yi Wu;Oyang Y.-J.;Juan H.-F.;Huang H.-C.; Lin C.-C.; Hsiang J.-T.; CHIA-YI WU; Oyang Y.-J.; Juan H.-F.; Huang H.-C. |
| 臺大學術典藏 |
2020-05-27T03:38:19Z |
The genetic structure, virulence, and fungicide sensitivity of Fusarium fujikuroi in Taiwan
|
Chen Y.-C.; Lai M.-H.; CHIA-YI WU; Lin T.-C.; Cheng A.-H.; Yang C.-C.; Wu H.-Y.; Chu S.-C.; Kuo C.-C.; Wu Y.-F.; Lin G.-C.; Tseng M.-N.; Tsai Y.-C.; Lin C.-C.; Chen C.-Y.; Huang J.-W.; Lin H.-A.; Chung C.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:31Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H;Cheng A.-L;Hsu C;Chih-Hsin Yang;Lu Y.-S;Lin C.-C;Bu C.-F;Yeh K.-H.; Hsu C.-H; Cheng A.-L; Hsu C; CHIH-HSIN YANG; Lu Y.-S; Lin C.-C; Bu C.-F; Yeh K.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:26Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Hsu C.-H; Cheng J.C; Wang H.-P; Lee J.-M; Yeh K.-H; CHIH-HSIN YANG; Lin J.-T; Cheng A.-L; Lee Y.-C.; Lin C.-C;Hsu C.-H;Cheng J.C;Wang H.-P;Lee J.-M;Yeh K.-H;Chih-Hsin Yang;Lin J.-T;Cheng A.-L;Lee Y.-C.; Lin C.-C |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C;Yeh K.-H;Chih-Hsin Yang;Hsu C;Tsai Y.-C;Hsu W.-L;Cheng A.-L;Hsu C.-H.; Lin C.-C; Yeh K.-H; CHIH-HSIN YANG; Hsu C; Tsai Y.-C; Hsu W.-L; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Lu Y.-S;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Chih-Hsin Yang; Lin C.-C; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Lin C.-C; Hsu C; Hsu C.-H; Hsu W.-L; Cheng A.-L; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:21Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Lin C.-C; Huang T.-C; Yang P.-C; CHIH-HSIN YANG; Yu C.-J; Shih J.-Y; Cheng A.-L; Hu F.-C; Kuo S.-H; Hsu C; Chih-Hsin Yang;Yang P.-C;Huang T.-C;Lin C.-C;Yu C.-J;Shih J.-Y;Cheng A.-L;Hu F.-C;Kuo S.-H;Hsu C |
| 臺大學術典藏 |
2020-05-26T09:27:21Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Chih-Hsin Yang;Cheng A.-L;Keng H.-Y;Hsu C.-H;Pu Y.-S;Lin C.-C; Lin C.-C; Pu Y.-S; Hsu C.-H; Keng H.-Y; Cheng A.-L; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:20Z |
National Center Of Excellence For Clinical Trials And Research At National Taiwan University Hospital
|
Lin C.-C; CHIH-HSIN YANG; Cheng A.-L; Chan W.-K; Ho H.-N. |
| 臺大學術典藏 |
2020-05-26T09:27:20Z |
National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital
|
Lin C.-C;Chih-Hsin Yang;Cheng A.-L;Chan W.-K;Ho N.-N.; Lin C.-C; CHIH-HSIN YANG; Cheng A.-L; Chan W.-K; Ho N.-N. |
| 臺大學術典藏 |
2020-05-26T09:27:19Z |
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer
|
Lin C.-C;Chih-Hsin Yang; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:18Z |
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors
|
Lin C.-C;Hsu H.-H;Sun C.-T;Shih J.-Y;Lin Z.-Z;Yu C.-J;Chen G.G;Hsin M.K.Y;Lam K.C;Leung L;Chih-Hsin Yang;Mok T.; Lin C.-C; Hsu H.-H; Sun C.-T; Shih J.-Y; Lin Z.-Z; Yu C.-J; Chen G.G; Hsin M.K.Y; Lam K.C; Leung L; CHIH-HSIN YANG; Mok T. |
| 臺大學術典藏 |
2020-05-26T09:27:17Z |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
|
Shao Y.Y;Lin C.C;Chih-Hsin Yang; Shao Y.Y; Lin C.C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:14Z |
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations
|
Lin C.-C;Chih-Hsin Yang; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:10Z |
Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC
|
Medema R.H;Lin C.-C;Chih-Hsin Yang; Medema R.H; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:03Z |
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
|
Liao B.-C;Lin C.-C;Chih-Hsin Yang; Liao B.-C; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:02Z |
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
|
Kao H.-F;Lin C.-C;Chih-Hsin Yang; Kao H.-F; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:00Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Lee J.-H; Lin Y.-L; Hsu W.-H; Chen H.-Y; Chang Y.-C; Yu C.-J; Shih J.-Y; Lin C.-C; Chen K.-Y; Ho C.-C; Laio W.-Y; Yang P.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:00Z |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
|
Ghamande S; Lin C.-C; Cho D.C; Shapiro G.I; Kwak E.L; Goel S.; Chuadhary I; Ghalib M.H; Cheng A.-L; CHIH-HSIN YANG; Coleman T; Silverman M.H; Tseng Y; Kuo M.-W; Mach W.B; Hsu S.-C |
| 臺大學術典藏 |
2020-05-26T09:26:59Z |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
|
CHIH-HSIN YANG; Kang J.H; Mok T; Ahn M.-J; Srimuninnimit V; Lin C.-C; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K. |
Showing items 1276-1300 of 2549 (102 Page(s) Totally)
<< < 47 48 49 50 51 52 53 54 55 56 > >>
View [10|25|50] records per page
